Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: Report on fluorescein angiographic findings

Ophthalmology

Volumn 121, Issue 11, 2014, Pages 2212-2219

  Lepore, Domenico ^a   Quinn, Graham E ^b   Molle, Fernando ^a   Baldascino, Antonio ^a   Orazi, Lorenzo ^a   Sammartino, Maria ^a   Purcaro, Velia ^a   Giannantonio, Carmen ^a   Papacci, Patrizia ^a   Romagnoli, Costantino ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FOLLOW UP; GESTATIONAL AGE; HUMAN; INFANT; LASER COAGULATION; NEWBORN INTENSIVE CARE; OPHTHALMOSCOPY; PREMATURITY; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULOPATHY; RETROLENTAL FIBROPLASIA; VISION; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG EFFECTS; EXTREMELY LOW BIRTH WEIGHT; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; NEWBORN; PATHOLOGY; PHOTOGRAPHY; RETINA BLOOD VESSEL; RETINAL DISEASES; RETINOPATHY OF PREMATURITY; SOLID STATE LASER; THERAPEUTIC USE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FLUORESCEIN ANGIOGRAPHY; GESTATIONAL AGE; HUMANS; INFANT, EXTREMELY LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE; INTRAVITREAL INJECTIONS; LASER COAGULATION; LASERS, SOLID-STATE; PHOTOGRAPHY; RETINAL DISEASES; RETINAL VESSELS; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84908897520     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.05.015     Document Type: Article

References (32)

1. L.E. Smith Pathogenesis of retinopathy of prematurity Semin Neonatol 8 2003 469 473
2. D. Lepore, F. Molle, and M.M. Pagliara Atlas of fluorescein angiographic findings in eyes undergoing laser for retinopathy of prematurity Ophthalmology 118 2011 168 175
3. Cryotherapy for Retinopathy of Prematurity Cooperative Group Multicenter trial of cryotherapy for retinopathy: preliminary results Arch Ophthalmol 106 1988 471 479
4. Early Treatment for Retinopathy of Prematurity Cooperative Group Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial Arch Ophthalmol 121 2003 1684 1696
5. S. Jalali, S. Kesarwani, and A. Hussain Outcomes of a protocol-based management for zone 1 retinopathy of prematurity: the Indian Twin Cities ROP Screening Program report number 2 Am J Ophthalmol 151 2011 719 724
6. G. Sanghi, M.R. Dogra, and P. Das Aggressive posterior retinopathy of prematurity in Asian Indian babies: spectrum of disease and outcome after laser treatment Retina 29 2009 1335 1339
7. J. Stone, A. Itin, and T. Alon Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia J Neurosci 15 1995 4738 4747
8. S. Hughes, H. Yang, and T. Chan-Ling Vascularization of the human fetal retina: role of vasculogenesis and angiogenesis Invest Ophthalmol Vis Sci 41 2000 1217 1228
9. N. Ferrara, K. Houck, L. Jakeman, and D.W. Leung Molecular and biological properties of the vascular endothelial growth factor family of proteins Endocr Rev 13 1992 18 32
10. A.L. Harris, P. Reusch, and B. Barleon Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy Clin Cancer Res 7 2001 1992 1997
11. A.P. Adamis, D.T. Shima, and M.J. Tolentino Inhibition of vascular endothelial growth factors prevents retinal ischemia-associated iris neovascularization in a nonhuman primate Arch Ophthalmol 114 1996 66 71
12. J. Stone, T. Chan-Ling, and J. Pe'er Role of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity Invest Ophthalmol Vis Sci 37 1996 290 299
13. L.G. Presta, H. Chen, and S.J. O'Connor Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 57 1997 4593 4599
14. Eyetech Study Group Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration Retina 22 2002 143 152
15. N. Ferrara, H.P. Gerber, and J. LeCouter The biology of VEGF and its receptors Nat Med 9 2003 669 676
16. S.J. Bakri, M.R. Snyder, and J.M. Reid Pharmacokinetics of intravitreal bevacizumab (Avastin) Ophthalmology 114 2007 855 859
17. P.K. Shah, V. Narendran, and K.A. Tawansy Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity Indian J Ophthalmol 55 2007 75 76
18. A. Travassos, S. Teixeira, and P. Ferreira Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity Ophthalmic Surg Lasers Imaging 38 2007 233 237
19. H.A. Mintz-Hittner, and R.R. Kuffel Jr. Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II Retina 28 2008 831 838
20. H. Quiroz-Mercado, M.A. Martinez-Castellanos, and M.L. Hernandez-Rojas Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity Retina 28 Suppl 2008 S19 25
21. E.J. Chung, J.H. Kim, H.S. Ahn, and H.J. Koh Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity Graefes Arch Clin Exp Ophthalmol 245 2007 1727 1730
22. J.C. Law, F.M. Recchia, and D.G. Morrison Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity J AAPOS 14 2010 6 10
23. G.A. Lalwani, A.M. Berrocal, and T.G. Murray Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity Retina 28 Suppl 2008 S13 S18
24. S. Kusaka, C. Shima, and K. Wada Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study Br J Ophthalmol 92 2008 1450 1455
25. R.M. Dafer, M. Schneck, T.R. Friberg, and W.M. Jay Intravitreal ranibizumab and bevacizumab: a review of risk Semin Ophthalmol 22 2007 201 204
26. B.A. Darlow, A.L. Ells, and C.E. Gilbert Are we there yet? Bevacizumab therapy for retinopathy of prematurity Arch Dis Child Fetal Neonatal Ed 98 2013 F170 F174
27. D.M. Moshfeghi, and A.M. Berrocal Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice Ophthalmology 118 2011 1227 1228
28. S. Honda, H. Hirabayashi, Y. Tsukahara, and A. Negi Acute contraction of the proliferative membrane after intravitreal injection of bevacizumab for advanced retinopathy of prematurity Graefes Arch Clin Exp Ophthalmol 246 2008 1061 1063
29. J. Hu, M.P. Blair, and M.J. Shapiro Reactivation of retinopathy of prematurity after bevacizumab injection Arch Ophthalmol 130 2012 1000 1006
30. T. Sato, K. Wada, and H. Arahori Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity Am J Ophthalmol 153 2012 327 333
31. H.A. Mintz-Hittner, K.A. Kennedy, A.Z. Chuang BEAT-ROP Cooperative Group Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity N Engl J Med 364 2011 603 615
32. S.G. Tahija, R. Hersetyati, and G.C. Lam Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity Br J Ophthalmol 98 2014 507 512